Enveric Biosciences, Inc. (ENVB)
ENVBNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.44
+0.0300 (+2.13%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $6.45m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.17 to $13.25
- Average volume
- 55.0k
- Previous close
- $1.41
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.87m | -$2.19m | -$1.63m | -$3.03m |
| Net income | -$1.87m | -$2.19m | -$1.63m | -$3.03m |
News
8 latest- Enveric Biosciences Moves Lead Neuroplastogenic Candidate Closer To Clinical Testing RTTNews · Oct 22, 2026
- Enveric Reports $1 Mln Loss In Q1; Advances EB-003 In Preclinical Studies RTTNews · May 15, 2026
- Morning Market Movers: HCAI, FATN, ENVB, AKAN See Big Swings RTTNews · Apr 30, 2026
- Enveric Closes $13.9 Million Private Placement To Advance Neuroplastogen Pipeline; Stock Up RTTNews · Apr 20, 2026
- Enveric's EB-003 Assay Data Shows Dual 5-HTA Pathway Engagement; Stock Up RTTNews · Feb 19, 2026
- Enveric Biosciences (ENVB) Price Target Increased by 1,100.00% to 122.40Fintel · Oct 29, 2025
- Enveric Biosciences Gets FDA Response On Request For Pre-IND Type B Meeting For Lead Program EB-003 RTTNews · Sep 16, 2025
- Enveric Biosciences Prices Public Offering At $3.00/Shr RTTNews · Jan 31, 2025
The company
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric's lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- enveric.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.